Download Internet Explorer 8 or Firefox 3 now!
Philip Bejon
kilifi [dot] kemri-wellcome [dot] org Research
I work with Ally Olotu, Roma Chilengi and Patricia Njuguna on a series of field trials on the candidate malaria vaccine RTS,S/AS01E. We have demonstrated efficacy against clinical malaria in a Phase IIb, proof-of-concept trial, and further studies are underway to examine the duration of protection, the correlates of immunity, and the interactions between vaccine induced protection and naturally acquired immunity. Kilifi is one of the sites involved in a Phase III trial to measure efficacy across Africa.
I also work with Jedidah Mwacharo and Oscar Kai on studies of vaccine induced immunity, in collaboration with the immunology group in Kilifi.
RTS,S is primarily and antibody inducing vaccine, but I have previously worked on T cell inducing candidate malaria vaccines, with a series of Phase I studies on vaccine safety and immunogenicity, and a Phase IIb study which did not demonstrate protection against clinical malaria in children.
We collaborate with GSK Biologicals (the owners of RTS,S) and the Malaria Vaccine Initiative on studies of RTS,S, and with Adrian Hill (University of Oxford) on studies of T cell inducing vaccines.
Collaborations
Publications
1. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, et al: Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008, 359:2521-2532.
2. Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, Musyoki JN, Bull P, Marsh K: Immunity to febrile malaria in children: an analysis that distinguishes immunity from lack of exposure. Infect Immun 2009.
3. O'Meara WP, Bejon P, Mwangi TW, Okiro EA, Peshu N, Snow RW, Newton CR, Marsh K: Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 2008, 372:1555-1562.
4. Bejon P, Mwacharo J, Kai O, Todryk S, Keating S, Lowe B, Lang T, Mwangi TW, Gilbert SC, Peshu N, et al: The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol 2007, 179:4193-4201.
5. Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, Maitland K, Williams T, Scott JA, English M, Lowe BS, et al: Defining childhood severe falciparum malaria for intervention studies. PLoS Med 2007, 4:e251.
6. Bejon P, Ogada E, Mwangi T, Milligan P, Lang T, Fegan G, Gilbert SC, Peshu N, Marsh K, Hill AV: Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE 2007, 2:e707.
7. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S, Keating S, Lang T, Lowe B, Gikonyo C, et al: A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS Clin Trials 2006, 1:e29